Comparative Pharmacology
Head-to-head clinical analysis: MICAFUNGIN versus MICAFUNGIN SODIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MICAFUNGIN versus MICAFUNGIN SODIUM.
MICAFUNGIN vs MICAFUNGIN SODIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits the synthesis of 1,3-β-D-glucan, an essential component of the fungal cell wall, via inhibition of 1,3-β-D-glucan synthase.
Micafungin inhibits 1,3-beta-D-glucan synthase, an enzyme required for synthesis of 1,3-beta-D-glucan, a key component of fungal cell walls.
100 mg intravenously once daily. For esophageal candidiasis: 150 mg intravenously once daily. Loading dose not required.
100 mg intravenously once daily; for invasive candidiasis, a loading dose of 200 mg intravenously once on day 1 may be considered.
None Documented
None Documented
Terminal elimination half-life is approximately 10-17 hours in healthy adults. In critically ill patients, it may be prolonged (up to 20-25 hours). Half-life is dose-independent.
Clinical Note
moderateMicafungin + Tranilast
"The risk or severity of adverse effects can be increased when Micafungin is combined with Tranilast."
Clinical Note
moderateMicafungin + Tolfenamic acid
"The risk or severity of adverse effects can be increased when Micafungin is combined with Tolfenamic acid."
Clinical Note
moderateMicafungin + Nimesulide
"The risk or severity of adverse effects can be increased when Micafungin is combined with Nimesulide."
Clinical Note
moderateMicafungin + Risedronic acid
Terminal elimination half-life: 11–17 hours (mean ~14 hours) in healthy adults; prolonged in moderate-to-severe hepatic impairment (up to 20–30 hours).
Primarily biliary/fecal (approximately 71% of administered dose recovered in feces as parent drug and metabolites), with renal excretion accounting for about 12% (mostly as metabolites, <1% unchanged). A small amount is excreted in urine.
Primarily hepatic metabolism; 71% recovered in feces (40% as parent drug, 31% as metabolite) and 11% in urine (1% as parent drug).
Category C
Category C
Antifungal (Echinocandin)
Antifungal (Echinocandin)
"The risk or severity of adverse effects can be increased when Micafungin is combined with Risedronic acid."